The latest research report by Emergen research, named ‘Global Cell-Free DNA (cfDNA) Testing Market – Forecast to 2027’, entails a comprehensive review of the global Cell-Free DNA (cfDNA) Testing market’s present and future trends. The latest report offers a profound analysis of the present market scenario, its key product types, end-user landscape, application outlook, leading regions, competitive terrain, and the leading companies’ detailed profiles. Region-wise, the performance of the industry along with the prominent vendors operating in the geography also illuminates stakeholders, business owners, and field marketing, executives. The different facets of the business based on parameters including new launches, acquisition and mergers and new entrants are discussed extensively during the study. The report emphasizes the demands and ongoing trends of the global Cell-Free DNA (cfDNA) Testing market, more importantly, across the major regions of the market. The global Cell-Free DNA (cfDNA) testing market is expected to grow significantly during the forecast period due to the increased incidence of cancers, rising prevalence of chromosome abnormalities in babies due to an increasing number of late pregnancy, and growing demand for non-invasive testing procedures. The report sheds light on the mergers and acquisitions, collaborations, joint ventures, brand promotions and product launches, agreements and partnerships, and corporate and government deals.
To get a sample copy of the Global Cell-Free DNA (cfDNA) Testing Market report, visit @ https://www.emergenresearch.com/request-sample/156
Based on the types, the Cell-Free DNA (cfDNA) Testing market has been further classified based on geography, application and consumption capability. On the basis of the product application, the industry is bifurcated taking into consideration those in demand and are an outcome of technology advancement. Additionally, our analysts have included SWOT analysis and Porter’s Five Forces analysis in the report to offer a better understanding of the competitive spectrum of this ever-evolving industry. The study performs a historical assessment of the Cell-Free DNA (cfDNA) Testing from 2017 to 2018, focusing on the market trends, revenue share, growth rate, production capacity, pricing structure, and other vital aspects during that period. Besides, the increasing investments by governments to implement advanced therapeutic technology in hospitals is also expected to boost the market during the forecast period.
To learn more details about the Global Cell-Free DNA (cfDNA) Testing Market report, visit @ https://www.emergenresearch.com/industry-report/cell-free-dna-market
The global Cell-Free DNA (cfDNA) Testing market report evaluates the latest economic scenario in terms of value and volume. It highlights the key growth drivers, restraints, production capacity, demand & supply ratio, import/export status, growth rate, and other critical aspects. Additionally, the report also performs SWOT analysis, Porter’s Five Forces analysis, speculation attainability investigation, and venture return investigation.
Key Highlights From The Report
- In August 2019, Agilent Technologies Inc. announced the acquisition of a leading manufacturer of innovative healthcare equipment, BioTek Instruments, Inc. This acquisition will expand Agilent’s product portfolio and its presence in North America.
- Cell-free fetal DNA is a non-invasive procedure and therefore does not pose a health risk of CVS (chorionic villus sampling) or amniocentesis, like pain and any slight chance of infection. Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Cell-Free DNA (cfDNA) testing market, in 2019.
- The MPSS technology segment is anticipated to dominate the global market with a CAGR of 26.7%, owing to the advantage of producing a measurable profile of gene expression in cells or tissues.